TICKERNERD
Menu
CGCCGCHealthcare · Drug Manufacturers - Specialty & Generic

CGC Stock Forecast: Canopy Growth Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.93
−0.25% on the day

The 8 Wall Street analysts covering Canopy Growth Corp. hold a median 12-month price target of $1.23 — +32.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$441.2M
Ticker Nerd rank
44 / 100
Median analyst target
$1.23
Analysts covering
8
Revenue$81.2M+12.5% y/y
Operating income−$17.6M
Net income−$14.6M
Free cash flow−$25.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.7%
1M
−7.2%
YTD
−18.6%
1Y
−33.3%
From 52W high
−51.7%
From 52W low
+8.2%
$0.86
$1.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Canopy Growth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
71
Accruals
67
Size
56
Growth
55
Issuance
51
Quality
51
Value
37
Volatility
18
Momentum
14

Revisions (71): Analysts have, on balance, been raising their forecasts.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.80$1.00$1.20$1.40$1.60$1.80Oct 25Jan 26Apr 26Jul 26CGCHigh $1.23Median $1.23Low $1.23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
2 Buy6 Hold0 Sell
Low $1.23Median $1.23High $1.23

The green dot is the last close — the median target sits +32.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 11 moved it down.

DateFirmActionRatingTarget
10 Nov 2025BenchmarkUpgradeHold—
27 Mar 2025Zuanic & AssociatesInitiatesNeutral—
9 July 2024Piper SandlerMaintainsUnderweight—
15 Sept 2023B of A SecuritiesMaintainsUnderperform$0.56 → $0.66
12 June 2023CIBCMaintainsUnderperformer$1.75 → $0.50
2 May 2023Piper SandlerMaintainsUnderweight$2.00 → $1.00
17 Feb 2023Cantor FitzgeraldMaintainsNeutral$3.30 → $3.20
7 Nov 2022Cantor FitzgeraldMaintainsNeutral$3.05 → $3.30
2 Nov 2022BernsteinInitiatesUnderperform$1.50
26 Oct 2022Cantor FitzgeraldMaintainsNeutral$2.90 → $3.05
30 Sept 2022BarclaysMaintainsUnderweight$3.50 → $2.00
8 Aug 2022Piper SandlerMaintainsUnderweight$3.00 → $2.50
30 June 2022Piper SandlerMaintainsUnderweight$4.00 → $3.00
8 June 2022BarclaysMaintainsUnderweight$6.00 → $3.50
31 May 2022Piper SandlerMaintainsUnderweight$6.00 → $4.00
22 Mar 2022BarclaysDowngradeUnderweight—
1 Mar 2022BarclaysMaintainsEqual-Weight$14 → $9.00
18 Feb 2022Cantor FitzgeraldMaintainsNeutral$9.60 → $11
22 Dec 2021B of A SecuritiesDowngradeUnderperform$19 → $10
20 Dec 2021Piper SandlerDowngradeUnderweight$11 → $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CGC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Canopy Growth Corp. returned −33.3% against +17.5% for the S&P 500, dividends included.

CGC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120130Oct 25Jan 26Apr 26Jul 26CGCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Canopy Growth Corp. (CGC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
1.4×

Cheaper than 61% of US stocks

Price / book
0.8×

Cheaper than 79% of US stocks

EV / EBITDA
−12.7×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
12.5%

Higher than 58% of US stocks

Earnings growth (YoY)
—
Gross margin
27.4%

Higher than 30% of US stocks

Operating margin
−21.7%

Higher than 21% of US stocks

Net margin
−79.2%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−39.5%

Higher than 24% of US stocks

Return on assets
−3.9%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Canopy Growth Corp. (CGC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Canopy Growth Corp. has a market value of $441.2M and an enterprise value of $239.3M.

  • Revenue in the twelve months to 30 June 2026: $293.6M. The latest quarter grew 12.5% year on year.

  • Net income over the same four quarters: −$236.0M, a −80.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.62.

  • Free cash flow in the twelve months to 30 June 2026: −$83.7M.

  • Shares outstanding: 423.0M.

  • Trailing P/E: −1.0×; forward P/E: −7.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Canopy Growth Corp. employs 1,128 people — $260K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

CGC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CGCCanopy Growth Corp.$441.2M
44
KMDAKamada Ltd.$464.5M
94
BIOABioAge Labs, Inc.$376.8M
40
TKNOAlpha Teknova, Inc.$359.8M
95
EOLSEvolus, Inc.$510.1M
88
EBSEmergent BioSolutions, Inc.$322.5M
86
TLRYTilray Brands, Inc.$547.5M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Canopy Growth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGC news & analysis

Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline

Business Wire · 14 Sept 2026neutral

Canopy Growth Corporation reminded shareholders to submit their votes by 1:00 p.m. ahead of its Annual General and Special Meeting scheduled for September 25, 2026, with a voting deadline of September 23. The meeting is set to take place virtually at 1:00 p.m. ET.

Why it matters — Shareholder participation in the upcoming Annual General and Special Meeting will determine key governance decisions for the company.

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

Business Wire · 8 Sept 2026positive

Canopy Growth announced an expansion of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, 7ACRES, Tweed, and Twd. brands, introducing two new product formats and new formulations within its existing oil and softgel ranges.

Why it matters — CGC watchers would care because this broadens Canopy Growth's medical cannabis product offerings in the Australian market, potentially strengthening its international footprint.

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted.

The Motley Fool · 7 Sept 2026positive

Canopy Growth reported 13% year-over-year revenue growth in its most recent fiscal quarter. Adjusted gross margin improved and EBITDA losses narrowed sharply, though investors showed little reaction.

Why it matters — The quarterly results indicate improving financial performance for Canopy Growth, with revenue growth, margin gains, and reduced losses that CGC watchers would view as progress.

Should You Buy Canopy Growth Stock on the Rebound?

The Motley Fool · 5 Sept 2026positive

Canopy Growth, a large Canadian marijuana company, has strengthened its financial position over the past year and completed an acquisition. The article discusses the company's recent progress amid its rebound.

Why it matters — A CGC watcher would care because the company's improved financial standing and acquisition signal changes in its business position that could affect its outlook.

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

The Motley Fool · 2 Sept 2026negative

The Motley Fool compares Canopy Growth and Tilray Brands as potential cannabis stock investments. It notes that Tilray derives more revenue from beverages than cannabis, while Canopy's debt situation drags down its growth potential.

Why it matters — CGC watchers would care because the piece highlights Canopy's debt as a factor weighing on its growth potential in an investor-focused comparison with rival Tilray.

FAQ

Frequently asked questions about CGC stock

What is the CGC stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Canopy Growth Corp. have a median 12-month price target of $1.23, with estimates ranging from $1.23 to $1.23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGC stock a buy right now?

Of the 8 analysts covering Canopy Growth Corp., 2 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Canopy Growth Corp. 44 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGC?

As at 12 Sept 2026, Canopy Growth Corp. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (71 of 100).

Will CGC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +32.1% from the last close, and Ticker Nerd's factor model ranks Canopy Growth Corp. 44 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGC stock forecast for 2030?

No analyst covering Canopy Growth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.23 to $1.23 over the next 12 months.

How has CGC stock performed over the past year?

Canopy Growth Corp. returned -33.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Canopy Growth Corp. do?

Canopy Growth Corporation is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-related products for medical and adult-use markets. Its business spans a range of product categories, including dried flower, oils, softgels, infused pre-rolls, and vaporizers, supported by brands such as Tweed, Doja, LivRelief, Ace Valley, and Deep Space.

What is the latest news on CGC?

The most recent item we track (Business Wire, 14 Sept 2026): "Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline". Canopy Growth Corporation reminded shareholders to submit their votes by 1:00 p.m. ahead of its Annual General and Special Meeting scheduled for September 25, 2026, with a voting deadline of September 23. The meeting is set to take place virtually at 1:00 p.m. ET.

Company

About Canopy Growth Corp.

Canopy Growth Corporation is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-related products for medical and adult-use markets. Its business spans a range of product categories, including dried flower, oils, softgels, infused pre-rolls, and vaporizers, supported by brands such as Tweed, Doja, LivRelief, Ace Valley, and Deep Space. The company operates through its Cannabis and Storz & Bickel segments, serving customers in Canada and selected international markets, including Europe and Germany. Canopy Growth also maintains a presence in medical cannabis and related wellness products, with an emphasis on regulated supply chains, branded consumer offerings, and international compliance capabilities. Headquartered in Smiths Falls, Ontario, Canopy Growth plays a notable role in the global cannabis market as a diversified producer and distributor with both medical and consumer-focused product lines.

CEO Mr. Luc Mongeau · 1,128 employees · Canada · https://www.canopygrowth.com